Starpharma Holdings Ltd has released a press release.
AZD0466 clinical DEP program global expansion
Filed with ASX ·
6ix hasn’t read this filing yet.
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- Change in substantial holding
- VIRALEZE COVID-19 nasal spray study to commence in January
- VIRALEZE COVID-19 nasal spray to be ready for market Q1CY21
- SPL7013 shows potent antiviral activity in RSV
- Completion of Placement and SPP raises $48.9M in total
Later from Starpharma
- Starpharma signs DEP ADC Research Agreement with MSD
- VIRALEZE antiviral nasal spray registered in Europe
- DEP HER2-lutetium outperforms in human breast cancer model
- VIRALEZE to be launched with LloydsPharmacy in the UK
- VIRALEZE™ now launched by LloydsPharmacy in the UK
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma